Issue Date: June 14, 2004
Symyx drug unit is now Ilypsa
Symyx Therapeutics, which applies high-throughput techniques to biopharmaceutical discovery, has changed its name to Ilypsa. The company has also appointed Scott M. Rocklage to be executive chairman. Rocklage is a partner in 5AM Ventures and the chairman of Cubist Pharmaceuticals. Additionally, Ilypsa, which had been working out of Symyx Technologies' facilities, is moving to its own 21,000-sq-ft space in Santa Clara, Calif. Investors in Ilypsa include the Sprout Group, Symyx Technologies, and 5AM Ventures.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society